AQST Aquestive Therapeutics, Inc.
Company Analysis
Latest News
Aquestive Therapeutics second quarter 2026 revenue of $13.8M missed estimates as Anaphylm resubmission remains on track
Aquestive Therapeutics reported second quarter 2026 revenue of $13.8 million, representing a 38% increase year-over-year but falling short of the $14.2 million...
🟢 Aquestive Therapeutics is trading 7.22% up today after positive Anaphylm results support FDA resubmission
Aquestive Therapeutics is trading 7.22% up now at $4.60 after positive Anaphylm human-factors and pharmacokinetic results supported its planned third-quarter...
🟢 Aquestive Therapeutics is trading 5.59% up in pre-market after positive Anaphylm results support planned FDA resubmission
Aquestive Therapeutics is trading 5.59% up now at $4.53 after positive Anaphylm human-factors and pharmacokinetic results supported a planned third-quarter...
🟢 Aquestive Therapeutics is trading 13.96% up today after Anaphylm studies cleared a key FDA hurdle
Aquestive Therapeutics is trading 13.96% up now at $4.49 after Anaphylm’s usability and drug-absorption studies cleared a key FDA hurdle, strengthening the...
🟢 Aquestive Therapeutics is trading 12% up in pre-market today after Anaphylm studies clear key FDA hurdle
Aquestive Therapeutics is trading 12.18% up now at $4.42 after its needle-free Anaphylm epinephrine film passed usability and drug-absorption studies, clearing...
Aquestive Clears a Key FDA Hurdle for Its Needle-Free Allergy Drug — But Can a $630 Million Company Really Take On EpiPen?
Shares of Aquestive Therapeutics jumped +9.1% to $4.30 Monday morning after the company reported that its under-the-tongue epinephrine film — a...
🟢 Aquestive Therapeutics is trading 9.14% up in pre-market after positive Anaphylm usability and pharmacokinetic results
Aquestive Therapeutics is trading at $4.30 (+9.14%) after announcing positive topline human-factors and pharmacokinetic study results for Anaphylm. - The data...
Aquestive Announces Positive Study Results for Anaphylm™, Plans Q3 NDA Resubmission
Aquestive Therapeutics announced positive topline results from its human factors (HF) and pharmacokinetic (PK) studies for Anaphylm™ (dibutepinephrine)...
Aquestive Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Wall Street analysts expect Aquestive Therapeutics to report Q2 2026 revenue of $14.22 million and a net loss of $0.11 per share, with the current $4.25 share...
🔴 Aquestive Therapeutics Inc is trading 5.66% down
AQST is trading at $4.00, down 5.66%.
Aquestive Bets Its Future on a Postage-Stamp-Sized Allergy Drug — But Can $160 Million in Fresh Capital Buy an FDA Yes?
Shares of Aquestive Therapeutics surged 9.3% in pre-market trading to $4.63, as investors renewed their focus on two financing deals designed to bankroll the...
🟢 Aquestive Therapeutics is trading 9.3% up today following SEC filing for warrant share resale
Aquestive Therapeutics is trading 9.3% up at $4.63 in pre-market sessions, following an SEC filing on July 9, 2026, for the registration of 230,271 warrant...
🔴 AQST is trading 5.1% down today as FDA setbacks and fraud lawsuits weigh on sentiment
AQST is trading at $4.17 (5.1% down) as investors remain cautious following regulatory and legal challenges surrounding its oral allergy drug, Anaphylm. •...
🔴 AQST is trading 5.2% down today as stalled FDA trajectory and lawsuits weigh on sentiment
AQST is trading at $4.24 (5.2% down) as the stock continues to slide following a sharp drop on June 25, 2026, driven by regulatory and legal concerns. •...
Aquestive's Allergy Drug Stalls at the FDA While Lawsuits Pile Up — Can Investors Afford to Wait for a Turnaround?
Shares of Aquestive Therapeutics sank another 11.6% to $4.41 on June 25, extending a brutal stretch for a company whose entire investment case hinges on a...
🔴 AQST is trading 11.6% down today on FDA deficiencies and fraud litigation overhangs
AQST is trading 11.62% down at $4.41 as the stock faces a renewed selloff tied to FDA-identified deficiencies in its Anaphylm NDA and ongoing securities-fraud...
🔴 AQST is trading 5.6% down today, extending weakness from the previous session
AQST is trading 5.6% down at $4.71 in pre-market, extending the weakness seen in the June 24 after-hours session as regulatory and legal overhangs persist. •...
🔴 AQST makes sharp 11.0% drop
AQST is trading at $4.44, down 11.0% versus the comparison close of $4.99 during after-hours. This is a price-movement alert; no separate company-specific...
🔴 AQST is trading 5.6% down today as a director sells over $125k in stock
• AQST is trading 5.6% down at $4.71 in after-hours sessions following a close of $4.99 on June 24, 2026. • The decline follows news of director Julie Krop...
🟢 Aquestive Therapeutics Inc is trading 5.2% up today on continued momentum and broader market gains
Aquestive Therapeutics Inc is trading 5.2% up at $4.66 on continued recent momentum and a positive broader market backdrop. • No fresh company-specific news,...